Ascentage Pharma Group International (AAPG)
| Market Cap | 1.58B -58.5% |
| Revenue (ttm) | 94.61M +64.5% |
| Net Income | -216.21M |
| EPS | -0.58 |
| Shares Out | 373.25M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,099 |
| Open | 17.70 |
| Previous Close | 17.62 |
| Day's Range | 17.60 - 17.75 |
| 52-Week Range | 16.23 - 41.40 |
| Beta | 0.67 |
| Analysts | Strong Buy |
| Price Target | 47.13 (+167.56%) |
| Earnings Date | Aug 19, 2026 |
About AAPG
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company’s primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid... [Read more]
Financial Performance
In 2025, AAPG's revenue was 574.12 million, a decrease of -41.46% compared to the previous year's 980.65 million. Losses were -1.24 billion, 206.5% more than in 2024.
Financial numbers in CNY Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for AAPG stock is "Strong Buy." The 12-month stock price target is $47.13, which is an increase of 167.56% from the latest price.
News
Ascentage Pharma to Participate in Four Upcoming Investor Conferences
ROCKVILLE, Md., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global, commercial-stage, integrated biophar...
Half Year 2026 Ascentage Pharma Group International Earnings Presentation Transcript
Half Year 2026 Ascentage Pharma Group International Earnings Presentation Transcript
Ascentage Pharma Group International H1 Earnings Call Highlights
Ascentage Pharma Group International NASDAQ: AAPG reported first-half 2026 revenue growth as it continued investing in global registrational studies for its hematology-oncology pipeline and began buil...
Ascentage Pharma Group International Earnings Call Transcript: H1 2026
Revenue grew 29% year-over-year to $44.5M, driven by product sales and expanding global trials. Cash runway extends through 2027, with multiple NDA filings expected next year. Key assets show strong differentiation and progress in both China and global markets.
Ascentage Pharma Group International Earnings release: H1 2026
Ascentage Pharma Group International released its H1 2026 earnings on August 20, 2026, summarizing the period's financial results.
Ascentage Pharma Group International Slides: H1 2026
Ascentage Pharma Group International has posted slides in relation to its H1 2026 quarterly earnings report, which was published on August 20, 2026.
Ascentage Pharma Loss H1 Revenue Jumps 29%; Advances Olverembatinib And Lisaftoclax Programs
(RTTNews) - Ascentage Pharma Group International (AAPG), a China-based commercial-stage biopharmaceutical company that develops therapies for cancer, reported interim financial results for the first h...
Ascentage Pharma Reports 2026 Interim Unaudited Financial Results and Provides Business Updates
Revenue for the first half of 2026 increased 29% year-over-year to US$44.5 million (RMB302.2 million), primarily attributable to increased product sales. Expanded executive leadership with appointment...
Ascentage Pharma to Participate in the Evercore 2nd Annual China Biotech Summit
ROCKVILLE, Md., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global, commercial-stage, integrated biopharm...
CORRECTION: Ascentage Pharma to Report 2026 Six Month Interim Results and Provide Corporate Update on August 19, 2026
In a release issued under the same headline earlier today by Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), please note that in the first paragraph of the release, the time should be...
Ascentage Pharma to Report 2026 Six Month Interim Results and Provide Corporate Update on August 19, 2026
ROCKVILLE, Md., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global, commercial-stage, integrated biopharm...
Ascentage Appoints Miyara As CBO And Ziegler As COO To Support Global Expansion
(RTTNews) - Ascentage Pharma Group International (AAPG) announced the appointment of Faiçal Miyara as Chief Business Officer (CBO) and Jim Ziegler as Chief Commercial Officer (COO) to support the deve...
Ascentage Pharma appoints Miyara as CBO, Ziegler as CCO
Ascentage Pharma (AAPG) Group announced the appointment of Faical Miyara, PhD, as Chief Business Officer, CBO, responsible for the Company’s global business development, and Jim Ziegler as Chief Comme...
Ascentage Pharma Appoints Dr. Faiçal Miyara as Chief Business Officer and Jim Ziegler as Chief Commercial Officer
ROCKVILLE, Md., Aug. 02, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the disco...
Ascentage Pharma Chairman and CEO Dr. Dajun Yang Named to The Medicine Maker Power List 2026
ROCKVILLE, Md. and SUZHOU, China, July 26, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company en...
Ascentage Pharma files to sell American Depositary Shares, no amount given
06:04 EDT Ascentage Pharma (AAPG) files to sell American Depositary Shares, no amount given
Ascentage Pharma assumed with an Outperform at Oppenheimer
Oppenheimer assumed coverage of Ascentage Pharma (AAPG) with an Outperform rating and $45 price target The firm notes Ascentage recently gave two oral presentations on olverembatinib at ASCO, as well…
Ascentage Pharma announces clinical updates from EHA2026
Ascentage Pharma (AAPG) announced that seventeen clinical updates from its core assets were presented at the 31st Congress of the European Hematology Association, EHA2026. Title: “Efficacy of Olveremb...
Ascentage Pharma Presents Multiple Clinical Updates at EHA2026 Congress
ROCKVILLE, Md. and SUZHOU, China, June 14, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company en...
Ascentage Pharma initiated with a Buy at B. Riley
B. Riley initiated coverage of Ascentage Pharma (AAPG) with a Buy rating and $45 price target The company has two drugs approved and selling in China and those same two…
Ascentage Pharma Group International Transcript: Jefferies Global Healthcare Conference 2026
Two novel products are commercialized in China, with multiple global Phase III trials underway for lead assets targeting hematologic malignancies. Recent clinical data show strong efficacy and safety, and U.S. commercialization is planned for 2028, with NDA filings expected next year.
Ascentage Pharma presents data on olverembatinib
Ascentage Pharma (AAPG) Group announced updated efficacy and safety data from a clinical study of its first approved product, olverembatinib, as a second-line therapy in patients with chronic-phase ch...
Ascentage Pharma presents data from Phase 1b study of olverembatinib
Ascentage Pharma (AAPG) Group announced results from a Phase Ib study evaluating olverembatinib, the company’s core product, in combination with bispecific T-cell engager antibody blinatumomab in pati...
Ascentage Pharma presents first dataset of alrizomadlin
Ascentage Pharma (AAPG) announced that the Company presented its first dataset of alrizomadlin, an MDM2-p53 inhibitor from the Company’s apoptosis-targeted pipeline, as monotherapy or in combination w...
Ascentage Pharma Presents Data on Olverembatinib in CML-LBP and Ph+ BCP-ALL at ASCO 2026
ROCKVILLE, Md. and SUZHOU, China, May 31, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company eng...